Innovotech Inc. · TSXV:IOT
Innovotech — Investor Presentation (May 2022)
16 slides from Innovotech's investor presentation, May 2022
Slide 1: A Profitable Revenue Platform
(TSX-V:IOT) A PROFITABLE REVENUE PLATFORM A GROWING ASSET PLATFORM A TAX PROTECTED PLATFORM Our plan is to use time, effort, discipline, and innovation to deliver a diversified Canadian Biotech. Updated May, 2022
Slide 2: Brief History
Brief History InnovoSIL™-1 • 20% revenue • 24% revenue IOT refinanced silver growth over growth over by Lonsdale antimicrobial • 20% revenue 2019 2020 IOT listed on Capital (acquires R&D phase growth over • Net profit: • Net profit: TSX-V 32% interest) completed + 2018 $106,317 $367,130 costs reduce
Slide 3: Our Business 1: Contract Research Organization
Our Business 1: Contract Research Organization Innovotech is a CRO. The Company is a leader in contract research testing of coated medical devices like implants for their susceptibility or resistance to the formation of microbial biofilms that cause chronic infections and disease in humans. • Innovo
Slide 4: 5 Year Trend: Revenue & Net Income
5 Year Trend: Revenue & $1,600,000 $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $0 -$200,000 -$400,000 2017 2018 2019 2020 2021 Net Income $753,385 -$127,634 -$48,761 $106,317 $367,130 Revenue $990,343 $826,935 $986,225 $1,203,382 $1,481,767 www.innovotech.ca
Slide 5: Our Business 2: MBEC Assay Kits & InnovoSIL-1 Silver
Our Business 2: MBEC Assay® Kits & InnovoSIL™-1 Silver MBEC ASSAY® KITS Innovotech makes and sells globally the MBEC Assay® Kits, a high throughput biofilm growth device. Any hard surface or disinfectant claiming effectiveness against biofilms must pass ASTM tests based on the Innovotech MBEC Assay®
Slide 6: A profitable, listed Canadian micro-cap biotech
A profitable, listed Canadian micro-cap biotech… In the twelve months to December 31st, 2021 Innovotech earned a profit of $367,130, or 1¢ per share. As noted, $85,995 of the 2021 profit was derived from an increase in the fair value of the Company’s CanBiocin debenture, which was converted into 120
Slide 7: 5 Year Trend: Shareholder's Equity
5 Year Trend: Shareholder’s Equity $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $0 2017 2018 2019 2020 2021 Shareholder's $181,508 $93,470 $98,087 $644,978 $1,176,930 Equity www.innovotech.ca
Slide 8: Recent Corporate Developments in R&D and Diversification
Recent Corporate Developments in R&D and Diversification Innovotech has used increasing profits, its strong balance sheet and treasury shares to diversify and to participate in products that may be applicable to consumer markets. Q1 2021: investment acquisition,-Nou Life Sciences Inc. In skin care,
Slide 9: External Growth Plan: Investment
External Growth Plan: Investment Innovotech is interested in right-sized investment opportunities such as the described probiotics and skin cream acquisitions to extend our reach, diversify our assets and open avenues to larger markets even if it is through indirect equity participation. • For Innov
Slide 10: Internal Lean Growth Plan
Internal Lean Growth Plan • Innovotech continues to work to add new accounts to our growing business and was successful at that in 2021. • We continue to work up devices and products to separate us from our competition and improve the quality and efficiency of our testing of client medical devices •
Slide 11: External Growth Plan: Acquisition
External Growth Plan: Acquisition The tax case Prior year’s NOLs and SRED tax credits provide a long-term tax pool of $7.2 million (Dec. 31, 2021) available to reduce our future net income for tax purposes. The pools can do the same for an acquired company. These pools do not start to expire until 2
Slide 12: 2 Year Trend: Quarterly Revenue & Net Income
2 Year trend: Quarterly Revenue & $600,000 $500,000 $400,000 $300,000 $200,000 $100,000 $0 -$100,000 -$200,000 Q1, 2021 Q2, 2021 Q3, 2021 Q4, 2021 Q1, 2022 Q2, 2022 Q3, 2022 Q4, 2022 Net Income -$115,298 $121,974 $93,218 $6,423 $22,235 $163,690 -$21,472 $202,677 Revenue $126,387 $333,904 $351,476 $3
Slide 13: Who we are
Who we are Officers & Management Directors Dr. James Timourian President Dr. James Timourian, PhD* Alan Savage CFO Alan Savage* Dr. Tyler Boone COO Dr. Gerard Tertzakian, PhD Dr. Patricia Nadworny CSO David Tam, BSc. Pharma, LLB Dr. Craig Milne, PhD, MBA Bernard Grobbelaar CPA Dr. Karen Farkas PhD *
Slide 14: Mission & Vision of Innovotech
Mission & Vision of Innovotech Scale up Innovotech to be a significant, innovative, profitable participant in the Canadian biotech sector • The time frame for the mission is not a short one. Innovotech has a knowledgeable, committed, invested and incentivized Board. It has a major shareholder and ma
Slide 15: Company Information
Company Information Share Capital Authorized Unlimited Issued 38,909,612 Directors hold as of AGM, October 12, 2021: James Timourian 2,085,812 Gerry Tertzakian 1,041,998 Craig Milne 160,000 Karen Farkas 15,000 Bernard Grobbelaar 65,000 David Tam 592,000 Alan Savage (through Lonsdale Capital) 13,180,
Slide 16: Disclaimer
Disclaimer This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking stat